Who owns HALOZYME THERAPEUTICS?
- CUSIP Number: 40637had1
Tip: Access positions for across all investors
Analyze quarterly positions in Halozyme Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Halozyme Therapeutics stock
Who bought or sold HALOZYME THERAPEUTICS this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| M&G | 37M | $38M | 1% | Mar 2026 |
|
| Citadel Advisors | 20M | $20M | -54% | Mar 2026 |
|
| Steelhead Partners | 19M | $20B | 100% | Mar 2026 |
|
| Nuveen | 12M | $13M | 0% | Mar 2026 |
|
| Silverback Asset Management | 11M | $12M | 13% | Mar 2026 |
|
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | 11M | $11M | 0% | Mar 2026 |
|
| Citigroup | 10M | $11M | 100% | Mar 2026 |
|
| Tpg Gp A | 10M | $10M | 100% | Mar 2026 |
|
| Point72 Asset Management | 7.5M | $7.8M | 0% | Mar 2026 |
|
| Balyasny Asset Management | 6.2M | $6.5M | 100% | Mar 2026 |
|
| Calamos Advisors | 5.7M | $5.9M | -1% | Mar 2026 |
|
| MacKay Shields | 5.4M | $5.6M | 3% | Mar 2026 |
|
| Huntington Asset Advisors | 5.1M | $5.7M | 72% | Jun 2026 |
|
| Colony | 3.8M | $3.9M | -1% | Mar 2026 |
|
| Water Island Capital | 3.0M | $3.1M | 0% | Mar 2026 |
|
| Pier 88 Investment Partners | 3.0M | $3.1M | 18% | Mar 2026 |
|
| Advent Capital Management | 2.8M | $3.0M | -34% | Mar 2026 |
|
| Bnp Paribas Investment Partners | 2.7M | $2.7M | 0% | Mar 2026 |
|
| FMR | 2.3M | $2.4M | 0% | Mar 2026 |
|
| Aequim Alternative Investments | 2.0M | $2.1M | 0% | Mar 2026 |
|
| Man Group | 1.9M | $1.9M | -5% | Mar 2026 |
|
| Wells Fargo & Company | 1.4M | $1.5M | 0% | Mar 2026 |
|
| SSI Investment Management | 1.3M | $1.3M | 0% | Mar 2026 |
|
| Kohlberg Kravis Roberts & Co | 915k | $953k | 0% | Mar 2026 |
|
| Universal- Beteiligungs- und Servicegesellschaft mbH | 750k | $781k | 0% | Mar 2026 |
|
| Bank Of Montreal | 634k | $663k | 100% | Mar 2026 |
|
| Calamos Wealth Management | 266k | $277k | 2% | Mar 2026 |
|
| Oppenheimer Asset Management | 170k | $176k | -3% | Mar 2026 |
|
| Wiley Bros.-aintree Capital | 130k | $135k | -1% | Mar 2026 |
|
| Cutler Capital Management | 110k | $114k | 0% | Mar 2026 |
|
| UBS Group | 64k | $66k | 100% | Mar 2026 |
|
| Capital Investment Advisory Services | 59k | $66k | 0% | Jun 2026 |
|
| Mariner Wealth Advisors | 59k | $61k | 0% | Mar 2026 |
|
| Stephens | 53k | $55k | 0% | Mar 2026 |
|
| Branch Banking & Trust Company | 38k | $39k | 0% | Mar 2026 |
|
| Balboa Wealth Partners | 28k | $29k | 0% | Mar 2026 |
|
| Ameriprise Financial | 22k | $23k | 0% | Mar 2026 |
|
| Commonwealth Equity Services | 20k | $21k | 0% | Mar 2026 |
|
| Mml Investors Services | 18k | $19k | 0% | Mar 2026 |
|
| Raymond James Financial | 18k | $19k | -47% | Mar 2026 |
|
| Morgan Stanley | 15k | $16k | 0% | Mar 2026 |
|
| MAI Wealth Advisors | 15k | $16k | 0% | Mar 2026 |
|
| Goldstein Advisors | 14k | $15k | 0% | Mar 2026 |
|
| Cetera Investment Advisers | 12k | $12k | 0% | Mar 2026 |
|
| Laffer Investments | 1.9k | $2.2M | -2% | Jun 2026 |
|
Who sold out of Halozyme Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Leucadia National Corporation | Dec 2025 | 2.3M | $2.5M |
| Lazard Asset Management | Dec 2025 | 1.4M | $15k |
| Flossbach Von Storch | Dec 2025 | 1.1M | $1.1M |
| Palisade Capital Management | Dec 2025 | 550k | $594k |
| Ares Systematic Credit | Dec 2025 | 200k | $217k |
| Barclays | Dec 2025 | 53k | $57k |
| Wealth Enhancement Advisory Services | Dec 2025 | 21k | $24k |
| Insigneo Advisory Services | Dec 2025 | 15k | $16k |